Biotron Limited

As of June 30, 2024, Biotron Limited carries a market capitalization of 34.29M, placing it among publicly traded companies globally. Its enterprise value stands at 33.90M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2024, Biotron Limited has 1.03B shares outstanding.

These figures are as of June 30, 2024.

As of June 30, 2024, Biotron Limited maintains a current ratio of 0.58, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -2.92, indicating conservative leverage, while an interest coverage ratio of -4,705.97 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2024. Return on assets (ROA) is negative at -148.49, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Biotron Limited's stock has declined approximately 50.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

These figures cover the twelve months ended June 30, 2024. EBITDA reached -5.11M, while operating income came in at -5.15M.

As of June 30, 2024, Biotron Limited holds 393,198.00 in cash and equivalents against 7,130.00 in total debt, resulting in a net debt position of -393,198.00. Total book value stands at -244,032.00, with working capital of -310,679.00 providing operational flexibility.

These figures cover the twelve months ended June 30, 2024. Total shareholder yield reaches 0.07, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Biotron Limited shareholders.

Biotron Limited's most recent stock split took place on March 5, 2025 with a 7:8 split ratio.